Genmab A/S (CPH:GMAB)
1,751.50
+6.50 (0.37%)
Sep 5, 2025, 4:59 PM CET
Genmab Revenue
Genmab had revenue of $925.00M USD in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.65B
Revenue Growth
+32.97%
P/S Ratio
4.65
Revenue / Employee
$1.36M
Employees
2,682
Market Cap
107.73B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk | 311.94B |
Coloplast | 27.87B |
Demant | 22.59B |
ALK-Abelló | 5.86B |
H. Lundbeck | 23.52B |
Zealand Pharma | 9.11B |
Ambu A/S | 5.96B |
Bavarian Nordic | 6.46B |
Genmab News
- 3 days ago - AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
- 3 days ago - Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - GlobeNewsWire
- 3 days ago - Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 11 days ago - Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 11 days ago - Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - GlobeNewsWire
- 11 days ago - Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Business Wire
- 25 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 4 weeks ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga